High-sensitivity troponin I Linked with Adverse CV Outcomes

Elevated concentrations of high-sensitivity troponin I (hsTnI) were associated with several adverse cardiovascular outcomes, new study results suggest.

“Evaluation of stable symptomatic outpatients with suspected coronary artery disease (CAD) may be challenging because they have a wide range of cardiovascular risk,” the authors wrote in their abstract. “The role of troponin testing to assist clinical decision making in this setting is unexplored.”

The researchers looked at blood samples from 4,021 participants with stable chest symptoms and suspected CAD for the Prospective Multicenter Imaging Study for Evaluation of Chest Pain (PROMISE). Participant hsTnI was analyzed relative to the study endpoints death, acute myocardial infarction (MI), or hospitalization for unstable angina by 1 year.

The authors reported that 98.6% of participants had measurable hsTnI concentrations. The analysis results indicated that higher hsTnI was associated with greater event probabilities for the study endpoints (death, acute MI, or hospitalization for unstable angina). Multivariable models showed that hsTnI concentrations were independently associated with the study endpoints (P<0.001), and that they were associated with near-term events compared to longer follow-up.

The study was published in the Journal of the American College of Cardiology.

Source: JACC